Quantcast

All Posts Tagged Tag: ‘Pharmaceutical Companies’

$650 Million Settlement Reached in Pradaxa Lawsuit

Boehringer Ingelheim Pharmaceuticals this week agreed to a settlement in the multi-district litigation over the drug Pradaxa. The company has agreed to pay $650 million to settle the lawsuits. Much of that money will be used to compensate patients who claim they were injured by Pradaxa. Around 1,600 people had filed individual lawsuits against Boehringer Ingelheim over Pradaxa as of …

Read More

Diabetes, Alzheimer’s Research May Yield Cures

A new research project valued at roughly $230 million may yield the answers for curing Alzheimer’s, diabetes, lupus, and arthritis. Eight of the largest U.S. pharmaceutical companies are collaborating on the project with the National Institute of Health and the U.S. government to conduct extensive research on Alzheimer’s patients. Pfizer Inc., Eli Lilly & Co., Merck, Sanofi, Johnson & Johnson, …

Read More

Johnson & Johnson to Pay $2.2 Billion Over Risperdal Claims

The U.S. Department of Justice and the U.S. Food and Drug Administration (FDA) today announced that Janssen Pharmaceuticals has plead guilty over the misbranding of the drug Risperdal. Janssen and its company, Johnson & Johnson, will pay a total of $2.2 billion to settle the matter. Around $485 million of the amount will be paid in the form of a …

Read More

Cholesterol Drug Tredaptive Pulled Worldwide

Less than one month ago, Merck, a major U.S. pharmaceutical company, announced that its cholesterol drug Tredaptive failed a major clinical trial. The drug is meant to improve heart health by increasing levels of “good” cholesterol, but the trial found that patients on the drug did not have a reduced risk of heart attack, stroke, necessary bypass surgery, or death, …

Read More

Diabetes Drug Approved by U.S. FDA Committee

A U.S. Food and Drug Administration (FDA) committee this week approved the drug canagliflozin for the treatment of adults with type 2 diabetes. The Endrocrinologic and Metabolic Drugs Advisory Committee of the FDA voted 10 to 5 to approve the drug. Canagliflozin, which Johnson & Johnson has given the proposed trade name of Invokana, will, if further approved by the …

Read More

Stroke Medication Approved by the U.S. FDA

A new anti-clotting drug has been approved by the U.S. Food and Drug Administration. Called apixaban and marketed by Bristol-Myers Squibb and Pfizer as Eliquis, the drug has been approved to reduce the risk of stroke and blood clots for patients with an irregular heart beat that is not caused by a heart valve problem. “Blood clots in the heart …

Read More

Merck Drug Fails Major Clinical Trial

Merck, a major U.S. pharmaceutical company, announced this week that its drug “Tredaptive” has failed a clinical trial. The trial was meant to test the drug for its ability to improve patients’ heart health by increasing their levels of “good” cholesterol. The trial, conducted at Oxford University and funded by Merck, looked at 25,673 patients at high risk for heart …

Read More

Asthma Drug Rejected by U.K.’s NICE

The U.K.’s National Institute for Health and Clinical Excellence (NICE) this weekend issued a draft guidance stating that it does not recommend omalizumab, an asthma medication marketed as Xolair by Novartis Pharmaceuticals. NICE is a U.K. health authority that publishes guidelines for the National Health Service. Omalizumab currently has a U.K. marketing authorization as an add-on therapy for persistent allergic …

Read More

Arthritis Drug Approved by the U.S. FDA

The U.S. Food and Drug Administration this week approved Xeljanz (tofacitinib) for the treatment of moderate to severe rheumatoid arthritis (RA) in adults who have not responded to methotrexate. The twice-daily pill works by blocking molecules known as “Janus kinases.” The approval was based on the medication’s approval was based on its demonstrated effectiveness and safety in seven clinical trials. …

Read More

Multiple Sclerosis Drug ‘Reboots’ the Immune System

New trials show that a cancer drug can be an effective treatment for multiple sclerosis (MS) by ‘rebooting’ patients’ immune systems. The results of two phase III clinical trials were published today in the journal The Lancet. The trials, sponsored by Genzyme and Bayer Schering Pharma, found that for patients who recently relapsed, using a drug called alemtuzumab saw new …

Read More

Cholesterol Drug Wins FDA Recommendation

Isis Pharmaceuticals recently announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) found the company’s drug, Kynamro (the trade name for mipomersen sodium) has been demonstrated to exhibit “sufficient” efficacy and safety for the treatment of Homozygous Familial Hypercholesterolemia (HoFH). HoFH is an aggressive, genetic cardiovascular disorder characterized by high levels of …

Read More

Cancer Treatment Kevetrin Begins Clinical Trials

Today the Cellceutix Corporation announced that its new anti-cancer drug candidate Kevetrin will soon be entering clinical trials at the Harvard Cancer Center’s Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center. Cellceutix is a biopharmaceutical company focused on small molecule drugs for the treatment of “unmet” medical conditions, such as drug-resistant cancers and autoimmune diseases. Kevetrin is Cellceutix’s name …

Read More

Page 1 of 212»